Word: generic
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...culmination of the “Say Yes to Drugs” campaign, which has been advertising its message in front of the Science Center for much of this week, came on Saturday with a benefit dance and speech in support of better global access to generic drugs...
...nostalgia for the quirkiness, uniqueness, idiosyncratic-ness of Harvard Square,” while perusing the book in the Coop earlier this week. “I was interested to see how all the independent places are gone, and how it’s become more homogenized and generic,” he said. “Now it’s like going anywhere else in the country.” Like New Jersey? Lambert referred to the current state of the Square as an “academic theme park,” catering primarily to Cambridge?...
...This system must change. Without a standardized means to require generic production of certain technologies, Harvard effectively endorses the needless death and suffering of millions of people in the developing world. Instead, when it licenses a compound to a biotech or pharmaceutical company, the university should mandate that the drug created from that compound be allowed to be produced generically in developing countries, a move that would inherently lower the drug’s price...
...According to Berkeley Law School Professor Amy Kapczynzki, enabling generic production would have minimal financial impact on universities and pharmaceutical companies. For example, in 2002, Africa comprised only 1.3 percent of the world pharmaceutical market, and Southeast Asia, China, and the Indian subcontinent comprised 6.7 percent. These markets are so small that the profits rendered from them are insignificant, indicating that, at essentially no cost to the university, Harvard can make a groundbreaking step toward reducing the cost of essential medicines in poor countries and set an example for other universities to follow...
...final end product they need, such as formulated pills or vaccines. It is systematic in its approach, sufficiently transparent to verify its effectiveness, and based on explicit metrics that measure the success of technology transfer by its impact on access and continued innovation; that removes legal barriers to generic production of Harvard technologies in resource-limited countries, using proactive licensing provisions to ensure that barriers such as follow-on patents and data exclusivity cannot be used to block such production...